← Back to patent-cliff list
Osavampator
Tier C — Watch / tradeOsavampator
Takeda Pharmaceutical Company Limited
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AMPAR
Indications (approved)：Major depressive disorder, Treatment-resistant depression, Depressive disorder
Regional status
US
Phase III
2025-01-22
EU
Phase III
2025-03-31
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Osavampator?
Approved indications include: Major depressive disorder, Treatment-resistant depression, Depressive disorder.
When does the Osavampator patent expire?
No public expiry year is available for Osavampator yet; this page updates once verified.
How do I get a quote for Osavampator intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01